The skin as a metabolic and immune-competent organ: Implications for drug-induced skin rash

References

• Adam J, Eriksson K, Schnyder B, Fontana S, Pichler W, Yerly D. 2012. Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur J Immunol. 42:1706–1716.
   PubMed Web of Science ®Google Scholar
• Baron J, Merk H. 2001. Drug metabolism in the skin. Curr Opin Allergy Clin Immunol. 1:287–291.
   PubMedGoogle Scholar
• Baron J, Wiederholt T, Heise R, Merk H, Bickers D. 2008. Expression and function of cytochrome p450-dependent enzymes in human skin cells. Curr Med Chem. 15:2258–2264.
   PubMed Web of Science ®Google Scholar
• Calne R, Sells R, Pena J, Davis D, Millard P, Herbertson B, Binns R, Davies D. 1969. Induction of immunological tolerance by porcine liver allografts. Nature 223:472–476.
   PubMed Web of Science ®Google Scholar
• Castrejon J, Berry N, El-Ghaiesh S, Gerber B, Pichler W, Park B, Naisbitt D. 2010. Stimulation of human T-cells with sulfonamides and sulfonamide metabolites . J Allergy Clin Immunol. 125:411–418.
   PubMed Web of Science ®Google Scholar
• Chen C, Hsiao Y, Wu T, Hsih M, Tassaneeyakul W, Jorns T, Sukasem C, Hsu C, Su S, Chang W, et al. 2017. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology 88:78–86.
   PubMed Web of Science ®Google Scholar
• Chen H, Grover S, Yu L, Walker G, Mutlib A. 2010. Bioactivation of lamotrigine in vivo in rat and in vitro in human liver microsomes, hepatocytes, and epidermal keratinocytes: Characterization of thioether conjugates by liquid chromatography/mass spectrometry and high field nuclear magnetic resonance spectroscopy. Chem Res Toxicol. 23:159–170.
   PubMed Web of Science ®Google Scholar
• Chen P, Lin J, Lu C, Ong C, Hsieh P, Yang C, Tai C, Wu S, Lu C, Hsu Y, et al. 2011. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 364:1126–1133.
   PubMed Web of Science ®Google Scholar
• Chen X, Tharmanathan T, Mannargudi B, Gou H, Uetrecht J. 2009. A study of the specificity of lymphocytes in nevirapine-induced skin rash. J Pharmacol Exp Ther. 331:836–841.
   PubMed Web of Science ®Google Scholar
• Chiou C, Yang L, Hung S, Chang Y, Kuo T, Ho H, Hu S, Hong H, Chung W. 2008. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: A study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol. 22:1044–1049.
   PubMed Web of Science ®Google Scholar
• Cho T, Uetrecht J. 2017. How reactive metabolites induce an immune response that sometimes leads to an idiosyncratic drug reaction. Chem Res Toxicol. 30:295–314.
   PubMed Web of Science ®Google Scholar
• Cho Y, Lin J, Chen Y, Chang C, Hsiao C, Chung W, Chu CY. 2014. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Amer Acad Dermatol. 70:539–548.
   PubMed Web of Science ®Google Scholar
• Chuang W, Strobel P, Gold R, Nix W, Schalke B, Kiefer R, Opitz A, Klinker E, Muller-Hermelink H, Marx A. 2005. A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol. 58:644–648.
   PubMed Web of Science ®Google Scholar
• Chung W, Chang W, Stocker S, Juo C, Graham G, Lee M, Williams K, Tian Y, Juan K, Jan Y, et al. 2015. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: Impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 74:2157–2164.
   PubMed Web of Science ®Google Scholar
• Chung W, Hung S. 2014. Genetic factors associated with severe cutaneous adverse reactions-reply. JAMA 312:2166.
   PubMed Web of Science ®Google Scholar
• Chung W, Hung S, Hong H, Hsih M, Yang L, Ho H, Wu J, Chen Y. 2004. Medical genetics: A marker for Stevens-Johnson syndrome. Nature 428:486.
   PubMed Web of Science ®Google Scholar
• Chung W, Hung S, Yang J, Su S, Huang S, Wei C, Chin S, Chiou C, Chu S, Ho H, et al. 2008. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 14:1343–1350.
   PubMed Web of Science ®Google Scholar
• Chung W, Pan R, Chu M, Chin S, Huang Y, Wang W, Chang J, Hung S. 2015. Oxypurinol-specific T-cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions. J Invest Dermatol. 135:2237–2248.
   PubMed Web of Science ®Google Scholar
• Chung W, Shih S, Chang C, Lin T, Huang Y, Chang S, Liu M, Ko Y, Deng M, Liau Y, et al. 2013. Clinico-pathologic analysis of Coxsackievirus a6 new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions. J Infect Dis. 208:1968–1978.
   PubMed Web of Science ®Google Scholar
• Chung W, Wang C, Dao R. 2016. Severe cutaneous adverse drug reactions. J Dermatol. 43:758–766.
   PubMed Web of Science ®Google Scholar
• Clausen B, Stoitzner P. 2015. Functional specialization of skin dendritic cell subsets in regulating T-cell responses. Front Immunol. 6:534.
   PubMed Web of Science ®Google Scholar
• Di Meglio P, Perera G, Nestle F. 2011. The multitasking organ: recent insights into skin immune function. Immunity 35:857–869.
   PubMed Web of Science ®Google Scholar
• Dietz L, Esser P, Schmucker S, Goette I, Richter A, Schnolzer M, Martin S, Thierse H. 2010. Tracking human contact allergens: From mass spectrometric identification of peptide-bound reactive small chemicals to chemical-specific naive human T-cell priming. Toxicol Sci. 117:336–347.
   PubMed Web of Science ®Google Scholar
• Duong T, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. 2017. Severe cutaneous adverse reactions to drugs. Lancet 390:1996–2011.
   PubMed Web of Science ®Google Scholar
• Elsheikh A, Castrejon L, Lavergne S, Whitaker P, Monshi M, Callan H, El-Ghaiesh S, Farrell J, Pichler W, Peckham D, et al. 2011. Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis. J Allergy Clin Immunol. 127:1543–1551.
   PubMed Web of Science ®Google Scholar
• Faulkner L, Gibson A, Sullivan A, Tailor A, Usui T, Alfirevic A, Pirmohamed M, Naisbitt D, Park B. 2016. Detection of primary T-cell responses to drugs and chemicals in HLA-typed volunteers: Implications for prediction of drug immunogenicity. Toxicol Sci. 154:416–429.
   PubMed Web of Science ®Google Scholar
• Faulkner L, Martinsson K, Santoyo-Castelazo A, Cederbrant K, Schuppe-Koistinen I, Powell H, Tugwood J, Naisbitt D, Park B. 2012. The development of in vitro culture methods to characterize primary T-cell responses to drugs. Toxicol Sci. 127:150–158.
   PubMed Web of Science ®Google Scholar
• Fernandez T, Canto G, Blanca M. 2009. Molecular mechanisms of maculopapular exanthema. Curr Opin Infect Dis. 22:272–278.
   PubMed Web of Science ®Google Scholar
• Gallucci S, Matzinger P. 2001. Danger signals: SOS to the immune system. Curr Opin Immunol. 13:114–119.
   PubMed Web of Science ®Google Scholar
• Genin E, Chen D, Hung S, Sekula P, Schumacher M, Chang P, Tsai S, Wu T, Bellon T, Tamouza R, et al. 2014. HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: An international study and meta-analysis. Pharmacogen J. 14:281–288.
   PubMed Web of Science ®Google Scholar
• Gibson A, Faulkner L, Lichtenfels M, Ogese M, Al-Attar Z, Alfirevic A, Esser PR, Martin SF, Pirmohamed M, Park B, et al. 2017. The effect of inhibitory signals on the priming of drug hapten-specific T-cells that express distinct Vβ receptors. J Immunol. 199:1223–1237.
   PubMed Web of Science ®Google Scholar
• Gibson A, Faulkner L, Wood S, Park B, Naisbitt D. 2017. Identification of drug- and drug-metabolite immune responses originating from both naive and memory T-cells. J Allergy Clin Immunol. 140:578–581.
   PubMed Web of Science ®Google Scholar
• Gibson A, Ogese M, Sullivan A, Wang E, Saide K, Whitaker P, Peckham D, Faulkner L, Park B, Naisbitt D. 2014. Negative regulation by PD-L1 during drug-specific priming of IL-22-secreting T-cells and the influence of PD-1 on effector T-cell function . J Immunol. 192:2611–2621.
   PubMed Web of Science ®Google Scholar
• Green V, Pirmohamed M, Kitteringham N, Gaedigk A, Grant D, Boxer M, Burchell B, Park B. 1995. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Biochem Pharmacol. 50:1353–1359.
   PubMed Web of Science ®Google Scholar
• Guo H, Callaway J, Ting J. 2015. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 21:677–687.
   PubMed Web of Science ®Google Scholar
• Hodi F, O'Day S, McDermott D, Weber R, Sosman J, Haanen J, Gonzalez R, Robert C, Schadendorf D, Hassel J, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363:711–723.
   PubMed Web of Science ®Google Scholar
• Hu T, Khambatta Z, Hayden P, Bolmarcich J, Binder R, Robinson M, Carr G, Tiesman J, Jarrold B, Osborne R, et al. 2010. Xenobiotic metabolism gene expression in the EpiDermin vitro 3D human epidermis model compared to human skin. Toxicol In Vitro 24:1450–1463.
   PubMed Web of Science ®Google Scholar
• Hung S, Chung W, Liou L, Chu C, Lin M, Huang H, Lin Y, Lan J, Yang L, Hong H, et al. 2005. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci. USA 102:4134–4139.
   PubMed Web of Science ®Google Scholar
• Illing P, Vivian J, Dudek N, Kostenko L, Chen Z, Bharadwaj M, Miles J, Kjer-Nielsen L, Gras S, Williamson N, et al. 2012. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 486:554–558.
   PubMed Web of Science ®Google Scholar
• Ju C, Uetrecht J. 1999. Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J Pharmacol Exp Ther. 288:51–56.
   PubMed Web of Science ®Google Scholar
• Kaniwa N, Saito Y. 2013. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury. J. Human Genetics 58:317–326.
   PubMed Web of Science ®Google Scholar
• Ko T, Chung W, Wei C, Shih H, Chen J, Lin C, Chen Y, Hung S. 2011. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol. 128:1266–1276.
   PubMed Web of Science ®Google Scholar
• Kongpan T, Mahasirimongkol S, Konyoung P, Kanjanawart S, Chumworathayi P, Wichukchinda N, Kidkeukarun R, Preechakul S, Khunarkornsiri U, Bamrungram W, et al. 2015. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogen Genomics 25:402–411.
   PubMed Web of Science ®Google Scholar
• Kouki T, Sawai Y, Gardine C, Fisfalen M, Alegre M, DeGroot L. 2000. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol. 165:6606–6611.
   PubMed Web of Science ®Google Scholar
• Lally A, Turner R. 2007. A survey of approach to wound healing by secondary intention among British Society for Dermatological Surgery members. Br J Dermatol. 156:575–576.
   PubMed Web of Science ®Google Scholar
• Lamoreux M, Sternbach M, Hsu W. 2006. Erythema multiforme. Am Fam Physician 74:1883–1888.
   PubMed Web of Science ®Google Scholar
• Landsteiner K, Jacobs J. 1935. Studies on the sensitization of animals with simple chemical compounds. J Exp Med. 61:643–656.
   PubMedGoogle Scholar
• Lin C, Chen J, Ko T, Wei C, Wu J, Chung W, Chen S, Liao Y, Hung S, Chen Y. 2015. Immuno-logic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T-cells and molecular interaction. J Allergy Clin Immunol. 135:1063–1065 e1065.
   PubMed Web of Science ®Google Scholar
• Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck J, Sidoroff A, de Toma C, et al. 2008. European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogen Genomics 18:99–107.
   PubMed Web of Science ®Google Scholar
• Lu W, Li X, Uetrecht J. 2008. Changes in gene expression induced by carbamazepine and phenytoin: Testing the danger hypothesis. J Immunotoxicol. 5:107–113.
   PubMed Web of Science ®Google Scholar
• Lu W, Uetrecht J. 2007. Possible bioactivation pathways of lamotrigine. Drug Metab Dispos. 35:1050–1056.
   PubMed Web of Science ®Google Scholar
• Lu W, Uetrecht J. 2008. Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin. Drug Metabol Disposit 36:1624–1636.
   PubMed Web of Science ®Google Scholar
• Lucas A, Lucas M, Strhyn A, Keane N, McKinnon E, Pavlos R, Moran E, Meyer-Pannwitt V, Gaudieri S, D'Orsogna L, et al. 2015. Abacavir-reactive memory T-cells are present in drug naïve individuals. PLoS One 10:e0117160
   PubMed Web of Science ®Google Scholar
• Mak A, Uetrecht J. 2015a. The combination of anti-CTLA-4 and PD1−/− mice unmasks the potential of isoniazid and nevirapine to cause liver injury. Chem Res Toxicol. 28:2287–2291.
   PubMed Web of Science ®Google Scholar
• Mak A, Uetrecht J. 2015b. Immunization with amodiaquine-modified hepatic proteins prevents amodiaquine-induced liver injury. J Immunotoxicol. 12:361–367.
   PubMed Web of Science ®Google Scholar
• Mallal S, Nolan D, Witt C, Masel G, Martin A, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, et al. 2002. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727–732.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, Molina J, Workman C, Tomazic J, Jagel-Guedes E, Rugina S, Kozyrev O, Cid J, et al. 2008. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J. Med 358:568–579.
   PubMed Web of Science ®Google Scholar
• Man S, Kanneganti T. 2015. Regulation of inflammasome activation. Immunol Rev. 265:6–21.
   PubMed Web of Science ®Google Scholar
• Martin S, Esser P, Schmucker S, Dietz L, Naisbitt D, Park B, Vocanson M, Nicolas J, Keller M, Pichler W, et al. 2010. T-Cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays. Cell Mol Life Sci. 67:4171–4184.
   PubMed Web of Science ®Google Scholar
• Matzinger P. 1998. An innate sense of danger. Semin Immunol. 10:399–415.
   PubMed Web of Science ®Google Scholar
• McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PIW, et al. 2011. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans . N Engl J Med 364:1134–1143.
   PubMed Web of Science ®Google Scholar
• Meng X, Al-Attar Z, Yaseen F, Jenkins R, Earnshaw C, Whitaker P, Peckham D, French N, Naisbitt D, Park B. 2017. Definition of the nature and hapten threshold of the β-lactic antigen required for t-cell activation in vitro and in patients. J Immunol. 198:4217–4227.
   PubMed Web of Science ®Google Scholar
• Metushi I, Hayes M, Uetrecht J. 2015. Treatment of PD-1(−/−) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology. 61:1332–1342.
   PubMed Web of Science ®Google Scholar
• Monshi M, Faulkner L, Gibson A, Jenkins R, Farrell J, Earnshaw C, Alfirevic A, Cederbrant K, Daly A, French N, et al. 2013. Human leukocyte antigen (HLA)-B*57:01-restricted activa-tion of drug-specific T-cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 57:727–739.
   PubMed Web of Science ®Google Scholar
• Naisbitt D, Farrell J, Wong G, Depta J, Dodd C, Hopkins J, Gibney C, Chadwick D, Pichler W, Pirmohamed M, et al. 2003. Characterization of drug-specific T-cells in lamotrigine hypersensitivity. J Allergy Clin Immunol. 111:1393–1403.
   PubMed Web of Science ®Google Scholar
• Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, Bagot M, Roujeau J. 2004. Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T-cells. J Allergy Clin Immunol. 114:1209–1215.
   PubMed Web of Science ®Google Scholar
• Negrini S, Becquemont L. 2017. HLA-associated drug hypersensitivity and the prediction of adverse drug reactions. Pharmacogenomics 18:1441–1457.
   PubMed Web of Science ®Google Scholar
• Newman W, Stoner G, Bloom B. 1977. Primary in vitro sensitisation of human T-cells. Nature 269:151–153.
   PubMed Web of Science ®Google Scholar
• Ng C, Yeh Y, Wang C, Hung S, Yang C, Chang Y, Chang W, Lin Y, Chang C, Su S, et al. 2016. Impact of the HLA-B(*)58:01 allele and renal impairment on allopurinol-induced cutaneous adverse reactions. J Invest Dermatol. 136:1373–1381.
   PubMed Web of Science ®Google Scholar
• Norcross M, Luo S, Lu L, Boyne M, Gomarteli M, Rennels A, Woodcock J, Margulies D, McMurtrey C, Vernon S, et al. 2012. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: An autoimmune model for HLA-associated drug hypersensitivity. AIDS 26:F21–F29.
   PubMed Web of Science ®Google Scholar
• Ogese M, Ahmed S, Alferivic A, Betts C, Dickinson A, Faulkner L, French N, Gibson A, Hirschfield G, Kammuller M, et al. 2017. New approaches to investigate drug-induced hypersensitivity. Chem Res Toxicol. 30:239–259.
   PubMed Web of Science ®Google Scholar
• Ostrov D, Grant B, Pompeu Y, Sidney J, Harndahl M, Southwood S, Oseroff C, Lu S, Jakoncic J, de Oliveira C, et al. 2012. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA. 109:9959–9964.
   PubMed Web of Science ®Google Scholar
• Pan R, Dao R, Hung S, Chung W. 2017. Pharmacogenomic advances in the prediction and prevention of cutaneous idiosyncratic drug reactions. Clin Pharmacol Ther. 102:86–97.
   PubMed Web of Science ®Google Scholar
• Pichler W. 2002. Pharmacological interaction of drugs with antigen-specific immune receptors: The p-i concept. Curr Opin Allergy Clin Immunol. 2:301–305.
   PubMed Web of Science ®Google Scholar
• Pichler W. 2003. Delayed drug hypersensitivity reactions. Ann Intern Med. 139:683–693.
   PubMed Web of Science ®Google Scholar
• Pichler W, Tilch J. 2004. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 59:809–820.
   PubMed Web of Science ®Google Scholar
• Saeki M, Saito Y, Nagano M, Teshima R, Ozawa S, Sawada J. 2002. mRNA expression of multiple cytochrome P450 isozymes in four types of cultured skin cells. Int Arch Allergy Immunol. 127:333–336.
   PubMed Web of Science ®Google Scholar
• Schnyder B, Burkhart C, Schnyder-Frutig K, von Greyerz S, Naisbitt D, Pirmohamed M, Park B, Pichler W. 2000. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T-cells from allergic individuals. J Immunol. 164:6647–6654.
   PubMed Web of Science ®Google Scholar
• Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler W. 1997. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T-cell clones. J Clin Invest. 100:136–141.
   PubMed Web of Science ®Google Scholar
• Seldin M, Rich R. 1978. Human immune responses to hapten-conjugated cells. I. Primary and secondary proliferative responses in vitro. J Exp Med. 147:1671–1683.
   PubMed Web of Science ®Google Scholar
• Sharma A, Novalen M, Tanino T, Uetrecht J. 2013. 12-OH-nevirapine sulfate, formed in the skin, is responsible for nevirapine-induced skin rash. Chem Res Toxicol. 26:817–827.
   PubMed Web of Science ®Google Scholar
• Shenton J, Popovic M, Chen J, Masson M, Uetrecht J. 2005. Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat. Chem Res Toxicol. 18:1799–1813.
   PubMed Web of Science ®Google Scholar
• Shenton J, Teranishi M, Abu-Asab M, Yager J, Uetrecht J. 2003. Characterization of a potential animal model of an idiosyncratic drug reaction: Nevirapine-induced skin rash in the rat. Chem Res Toxicol. 16:1078–1089.
   PubMed Web of Science ®Google Scholar
• Shiohara T, Inaoka M, Kano Y. 2006. Drug-induced hypersensitivity syndrome (DIHS): A reaction induced by a complex interplay among herpesviruses and anti-viral and antidrug immune responses. Allergol Intl. 55:1–8.
   PubMedGoogle Scholar
• Su S, Mockenhaupt M, Wolkenstein P, Dunant A, le Gouvello S, Chen C, Chosidow O, Valeyrie-Allanore L, Bellon T, Sekula P, et al. 2017. IL-15 is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrosis. J Invest Dermatol. 137:1065–1073.
   PubMed Web of Science ®Google Scholar
• Sullivan A, Wang E, Farrell J, Whitaker P, Faulkner L, Peckham D, Park B, Naisbitt D. 2018. β-lactam hypersensitivity involves expansion of circulating and skin-resident TH22 cells. J Allergy Clin Immunol. 141:235–249.
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Jantararoungtong T, Chen P, Lin P, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, et al. 2009. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogen Genomics. 19:704–709.
   PubMed Web of Science ®Google Scholar
• Tate S, Singh R, Hung C, Tai J, Depondt C, Cavalleri G, Sisodiya S, Goldstein D, Liou H. 2006. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics. 16:721–726.
   PubMed Web of Science ®Google Scholar
• Ueta M, Kannabiran C, Wakamatsu T, Kim M, Yoon K, Seo K, Joo C, Sangwan V, Rathi V, Basu S, et al. 2014. Trans-ethnic study confirmed independent associations of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe ocular surface complications. Sci Rep. 4:5981
   PubMed Web of Science ®Google Scholar
• Watanabe H, Gaide O, Petrilli V, Martinon F, Contassot E, Roques S, Kummer J, Tschopp J, French L. 2007. Activation of the IL-1β-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol. 127:1956–1963.
   PubMed Web of Science ®Google Scholar
• Wei C, Chung W, Huang H, Chen Y, Hung SI. 2012. Direct interaction between HLA-B and carbamazepine activates T-cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol. 129:1562–1569. e1565.
   PubMed Web of Science ®Google Scholar
• Weston J, Uetrecht J. 2014. Activation of inflammasomes by agents causing idiosyncratic skin reactions: a possible biomarker. Chem Res Toxicol. 27:949–951.
   PubMed Web of Science ®Google Scholar
• Whitaker P, Meng X, Lavergne S, El-Ghaiesh S, Monshi M, Earnshaw C, Peckham D, Gooi J, Conway S, Pirmohamed M, et al. 2011. Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis. J Immunol. 187:200–211.
   PubMed Web of Science ®Google Scholar
• White K, Chung W, Hung S, Mallal S, Phillips E. 2015. Evolving models of the immunopathogenesis of T-cell-mediated drug allergy: the role of host, pathogens, and drug response. J Allergy Clin Immunol. 136:219–234.
   PubMed Web of Science ®Google Scholar
• Yang C, Hung S, Juo C, Lin Y, Fang W, Lu I, Chen S, Chen Y. 2007. HLA-B*1502-bound peptides: Implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol. 120:870–877.
   PubMed Web of Science ®Google Scholar
• Yang C, Chen C, Deng S, Huang C, Lin Y, Chen Y, Wu C, Hung S, Chung W. 2015. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan. JAMA Intern Med. 175:1550–1557.
   PubMed Web of Science ®Google Scholar
• Yip V, Pirmohamed M. 2017. The HLA-A*31:01 allele: Influence on carbamazepine treatment. Pharmgenomics Pers Med. 10:29–38.
   PubMed Web of Science ®Google Scholar
• Yip V, Meng X, Maggs J, Jenkins R, Marlot P, Marson A, Park B, Pirmohamed M. 2017. Mass spectrometric characterization of circulating covalent protein adducts derived from epoxide metabolites of carbamazepine in patients. Chem Res Toxicol. 30:1419–1435.
   PubMed Web of Science ®Google Scholar
• Yun J, Mattsson J, Schnyder K, Fontana S, Largiader C, Pichler W, Yerly D. 2013. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T-cell response. Clin Exp Allergy. 43:1246–1255.
   PubMed Web of Science ®Google Scholar
• Zanni M, von Greyerz S, Schnyder B, Brander K, Frutig K, Hari Y, Valitutti S, Pichler W. 1998. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human α β T lymphocytes. J Clin Invest. 102:1591–1598.
   PubMed Web of Science ®Google Scholar
• Zhang F, Liu H, Irwanto A, Fu X, Li Y, Yu G, Yu Y, Chen M, Low H, Li J, et al. 2013. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med. 369:1620–1628.
   PubMed Web of Science ®Google Scholar